CRBP - Corbus Pharmaceuticals

-

$undefined

N/A

(N/A)

Corbus Pharmaceuticals NasdaqCM:CRBP Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Location: 500 River Ridge Drive, Norwood, MA, 02062, United States | Website: https://www.corbuspharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-36.69M

Cash

132.8M

Avg Qtr Burn

-12.56M

Short % of Float

25.04%

Insider Ownership

0.51%

Institutional Own.

93.23%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 1b

Initiation

Phase 1

Data readout

CRB-701 (SYS6002) Details
Solid tumor/s, Urothelial cancer, Cancer

Phase 1

Update

Failed

Discontinued

Lenabasum Details
Genetic disorder, Chronic inflammatory disorder, Rare genetic disease, Inflammatory disease

Failed

Discontinued

Lenabasum Details
Systemic sclerosis

Failed

Discontinued

Lenabasum Details
Cystic fibrosis

Failed

Discontinued